- Home
- SLN vs EPRX Comparison
SLN vs EPRX Comparison
Compare SLN & EPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLN
- EPRX
- Stock Information
- Founded
- SLN 1994
- EPRX 2011
- Country
- SLN United Kingdom
- EPRX Canada
- Employees
- SLN N/A
- EPRX N/A
- Industry
- SLN Biotechnology: Pharmaceutical Preparations
- EPRX
- Sector
- SLN Health Care
- EPRX
- Exchange
- SLN Nasdaq
- EPRX NYSE
- Market Cap
- SLN 123.3M
- EPRX 130.0M
- IPO Year
- SLN N/A
- EPRX N/A
- Fundamental
- Price
- SLN $3.14
- EPRX $3.29
- Analyst Decision
- SLN Buy
- EPRX Strong Buy
- Analyst Count
- SLN 5
- EPRX 1
- Target Price
- SLN $40.80
- EPRX $9.00
- AVG Volume (30 Days)
- SLN 292.1K
- EPRX 8.3K
- Earning Date
- SLN 05-15-2025
- EPRX 05-07-2025
- Dividend Yield
- SLN N/A
- EPRX N/A
- EPS Growth
- SLN N/A
- EPRX N/A
- EPS
- SLN N/A
- EPRX N/A
- Revenue
- SLN $43,258,000.00
- EPRX N/A
- Revenue This Year
- SLN N/A
- EPRX N/A
- Revenue Next Year
- SLN N/A
- EPRX N/A
- P/E Ratio
- SLN N/A
- EPRX N/A
- Revenue Growth
- SLN 36.71
- EPRX N/A
- 52 Week Low
- SLN $1.97
- EPRX $2.20
- 52 Week High
- SLN $24.38
- EPRX $4.48
- Technical
- Relative Strength Index (RSI)
- SLN 49.25
- EPRX N/A
- Support Level
- SLN $2.63
- EPRX N/A
- Resistance Level
- SLN $2.95
- EPRX N/A
- Average True Range (ATR)
- SLN 0.43
- EPRX 0.00
- MACD
- SLN 0.11
- EPRX 0.00
- Stochastic Oscillator
- SLN 72.67
- EPRX 0.00
About SLN Silence Therapeutics Plc American Depository Share
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.
About EPRX EUPRAXIA PHARMACEUTICALS INC
Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to existing pharmaceuticals. Its product EP-104 is used for the treatment of osteoarthritis and eosinophilic esophagitis symptoms. The company leverages its proprietary Diffusphere technology to optimize drug delivery for applications with significant unmet medical needs.